2013-01-14 07:02:21 -

Not Intended for US Media

Oslo, Norway, 14 January 2013 - Algeta ASA (OSE: ALGETA) announces that the US
Nuclear Regulatory Commission (NRC) has issued a licensing decision on the
medical use of radium-223 dichloride (radium-223). The NRC licensing decision
follows the recommendation from the Advisory Committee on the Medical Use of
Isotopes (ACMUI) report, dated 20 November 2012.

Radium-223 is  an  investigational  agent  and  is  not approved by the European
Medicines  Agency  (EMA),  the  US  Food  and Drug Administration (FDA) or other
health authorities.

The  US NRC has ruled that sites can procure and administer radium-223 under 10
CFR  Part 35, Subpart E, which includes 10 CFR  § 35.300. It has also ruled that
physicians   authorized under 10 CFR § 35.390 or 10 CFR § 35.396 can be authorized
for  the medical use of radium-223. The US NRC has notified the Agreement States
regarding their licensing decision on radium-223.

In December 2012, Bayer submitted a Marketing Authorization Application (MAA) to
the  European Medicines Agency (EMA) and a  New Drug Application (NDA) to the US
Food   and  Drug  Administration  (FDA)  for  radium-223 for  the  treatment  of
castration-resistant  prostate  cancer  (CRPC)  patients  with  bone metastases.
Radium-223 has been granted fast track designation for this indication by FDA.

                                      ###

About Radium-223 Dichloride
Radium-223 dichloride  (radium-223), formerly  referred  to  as Alpharadin, is a
therapeutic  alpha  particle-emitting  pharmaceutical  with  targeted anti-tumor
effect on bone metastases in development for CRPC patients with bone metastases.

In  September 2009, Algeta  signed an  agreement with  Bayer Pharma  AG (Berlin,
Germany)  for  the  development  and  commercialization of radium-223. Under the
terms  of the agreement,  Bayer will develop,  apply for global health authority
approvals, and commercialize radium-223 globally. Algeta will co-promote radium-
223 with Bayer in the US, and is eligible for milestones as well as royalties on
Bayer's sales outside the US. The ALSYMPCA trial was initiated by Algeta in June
2008.

For further information, please contact:

 Mike Booth                           +47 2202 4510

 Communications & Corporate Affairs   ir@algeta.com



 Media enquiries:

 Mark Swallow                         +44 207 638 9571

 Citigate Dewe Rogerson               mark.swallow@citigatedr.co.uk



 Knut Ekern                           +47 22 04 82 00

 Gambit Hill & Knowlton               knut.ekern@hkstrategies.com



 US investor enquiries:

 Tricia Swanson                       +1 646 378 2953

 The Trout Group                      tswanson@troutgroup.com



About Algeta

Algeta  is a company focused on developing novel targeted therapies for patients
with   cancer  based  on  its  alpha-pharmaceutical  platform.  The  Company  is
headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in
Cambridge,  MA performing commercial  marketing operations in  the US. Algeta is
listed  on the Oslo Stock Exchange (Ticker: ALGETA). For more information please
visit www.algeta.com.

Forward-looking Statements

This  news release contains certain forward-looking statements that are based on
uncertainty,  as they  relate to  events and  depend on  circumstances that will
occur in the future and which, by their nature, may have an impact on results of
operations   and   the  financial  condition  of  Algeta.  Such  forward-looking
statements  reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance as to whether such forward
looking  statements will prove  to be correct.  These forward looking statements
include  statements regarding our anticipated  co-promotion of radium-223 in the
US.   There  are  a  number  of  factors  that  could  cause  actual results and
developments  to  differ  materially  from  those  expressed or implied by these
forward-looking  statements. These factors include, among other things, risks or
uncertainties  associated with  the ability  to identify  and hire  a sufficient
number of qualified employees for the US field force, growth management, general
economic  and business  conditions and  the pricing  environment, the  impact of
competition, the ability to successfully commercialize radium-223, the risk that
costs  associated  with  the  co-promotion  of  radium-223 may  be  greater than
anticipated, manufacturing capacity, the risk of non-approval of patents not yet
granted,  risks in obtaining  regulatory approvals for  radium-223 and the other
risks and uncertainties described in our annual report.


This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Press release: 
 hugin.info/134655/R/1669998/542661.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1669998]